methyl 4-(hydroxy(4-bromophenyl)methyl)benzoate | 1246271-86-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 4-(hydroxy(4-bromophenyl)methyl)benzoate
• 英文别名: 4-methoxycarbonylphenyl(4-bromophenyl)methanol；Methyl 4-[(4-bromophenyl)-hydroxymethyl]benzoate
• CAS: 1246271-86-2；872254-99-4
• 化学式: C₁₅H₁₃BrO₃
• 分子量: 321.17
• InChiKey: RKTSLFPDDYHAMT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 4-(hydroxy(4-bromophenyl)methyl)benzoate 在 三乙基硅烷 、 三氟甲磺酸 作用下， 以 氯仿 为溶剂， 反应 1.0h， 以70%的产率得到methyl 4-(4-bromobenzyl)benzoate
  参考文献：
  名称：

  Discovery of 1,1′-Biphenyl-4-sulfonamides as a New Class of Potent and Selective Carbonic Anhydrase XIV Inhibitors

  摘要：

  New 1,1'-biphenylsulfonamides were synthesized and evaluated as inhibitors of the ubiquitous human carbonic anhydrase isoforms I, II, IX, XII, and XIV using acetazolamide (AAZ) as reference compound. The sulfonamides 1-21 inhibited all the isoforms, with K-i values in the nanomolar range of concentration, and were superior to AAZ against all of them. X-ray crystallography and molecular modeling studies on the adducts that compound 20, the most potent hCA XIV inhibitor of the series (K-i, = 0.26 nM), formed with the five hCAs, provided insight into the molecular determinants responsible for the high affinity of this molecule toward the target enzymes. The results pave the way to the development of 1.1'-biphenylsulfonamides as a new class of highy potent hCA XIV inhibitors.

  DOI：

  10.1021/acs.jmedchem.5b01144
• 作为产物：
  描述：

  4-溴-4-甲基苯甲酮 在 sodium tetrahydroborate 、 potassium permanganate 、 硫酸 作用下， 以 四氢呋喃 、 水 、 叔丁醇 为溶剂， 反应 17.0h， 生成 methyl 4-(hydroxy(4-bromophenyl)methyl)benzoate
  参考文献：
  名称：

  Discovery of 1,1′-Biphenyl-4-sulfonamides as a New Class of Potent and Selective Carbonic Anhydrase XIV Inhibitors

  摘要：

  New 1,1'-biphenylsulfonamides were synthesized and evaluated as inhibitors of the ubiquitous human carbonic anhydrase isoforms I, II, IX, XII, and XIV using acetazolamide (AAZ) as reference compound. The sulfonamides 1-21 inhibited all the isoforms, with K-i values in the nanomolar range of concentration, and were superior to AAZ against all of them. X-ray crystallography and molecular modeling studies on the adducts that compound 20, the most potent hCA XIV inhibitor of the series (K-i, = 0.26 nM), formed with the five hCAs, provided insight into the molecular determinants responsible for the high affinity of this molecule toward the target enzymes. The results pave the way to the development of 1.1'-biphenylsulfonamides as a new class of highy potent hCA XIV inhibitors.

  DOI：

  10.1021/acs.jmedchem.5b01144

文献信息

• Cobalt-Catalyzed Addition Reaction of Organoboronic Acids with Aldehydes: Highly Enantioselective Synthesis of Diarylmethanols
  作者：Jaganathan Karthikeyan、Masilamani Jeganmohan、Chien-Hong Cheng

  DOI：10.1002/chem.201001160

  日期：——

  Predicted outcomes: The addition reaction of organoboronic acids with aldehydes in the presence of K2CO3 catalyzed by CoI2/(R,R)‐BDPP gives chiral secondary alcohols in excellent yields with 90–99 % enantiomeric excess (see scheme; (R,R)‐BDPP=(2R,4R)‐(+)‐2,4‐bis(diphenylphosphino)pentane). This method provides an alternative to prepare an R and S enantiomeric pair by using the same chiral ligand and

  预期的结果：在CoI 2 /（R，R）-BDPP催化下，在存在K 2 CO 3的情况下，有机硼酸与醛的加成反应可得到出色的手性仲醇，对映体过量90-99％（参见方案；（R，R）-BDPP =（2 R，4 R）-（+）-2,4-双（二苯基膦基）戊烷）。该方法提供了另一种通过使用相同的手性配体制备R和S对映体对的方法，并且可以预测反应的立体化学结果。
• [EN] GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES<br/>[FR] ANTAGONISTE DES RECEPTEURS DU GLUCAGON, PREPARATION ET UTILISATIONS THERAPEUTIQUES
  申请人：LILLY CO ELI

  公开号：WO2005123668A1

  公开（公告）日：2005-12-29

  The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.

  本发明公开了具有胰高血糖素受体拮抗剂或逆拮抗剂活性的化合物I的新化合物，或其药用可接受的盐，以及制备这些化合物的方法。在另一实施例中，本发明公开了包含化合物I的药物组合物，以及使用它们治疗糖尿病和其他与胰高血糖素相关的代谢性疾病等方法。
• Glucagon Receptor Antagonists, Preparation and Therapeutic Uses
  申请人：Conner Eugene Scott

  公开号：US20070249688A1

  公开（公告）日：2007-10-25

  The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.

  本发明公开了化合物I式的新型化合物，或其药学上可接受的盐，其具有葡萄糖高素受体拮抗剂或反向激动剂活性，以及制备这些化合物的方法。在另一种实施方式中，本发明还公开了包括I式化合物的药物组合物，以及使用它们治疗糖尿病和其他与葡萄糖高素相关的代谢性疾病的方法等。
• GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES
  申请人：CONNER Scott Eugene

  公开号：US20110124648A1

  公开（公告）日：2011-05-26

  The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.

  本发明披露了式I的新型化合物或其药学上可接受的盐，其具有胰高血糖素受体拮抗剂或反向激动剂活性，以及制备这种化合物的方法。在另一种实施方式中，本发明还披露了包含式I化合物的药物组合物，以及使用它们治疗糖尿病和其他胰高血糖素相关代谢紊乱等疾病的方法。
• Glucagon receptor antagonists, preparation and therapeutic uses
  申请人：Eli Lilly & Company

  公开号：EP2159221A1

  公开（公告）日：2010-03-03

  The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using these compounds and compositions to treat diabetic and other glucagon related metabolic disorders, and the like.

  本发明公开了具有胰高血糖素受体拮抗剂或反向激动剂活性的新型式 I 化合物或其药学上可接受的盐，以及制备此类化合物的方法。在另一个实施方案中，本发明公开了包含式 I 化合物的药物组合物，以及使用这些化合物和组合物治疗糖尿病和其他胰高血糖素相关代谢紊乱等疾病的方法。